CompletedPhase 2NCT00055653
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
Studying Tumor of hematopoietic and lymphoid tissues
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Roswell Park Cancer Institute
- Principal Investigator
- Philip L. McCarthy, MDRoswell Park Cancer Institute
- Intervention
- anti-thymocyte globulin(biological)
- Eligibility
- 17 years · All sexes
- Timeline
- 2003 – 2005
Study locations (25)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Children's Medical Center, University of California San Francisco, San Francisco, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Indiana University Cancer Center, Indianapolis, Indiana, United States
- Children's Hospital of New Orleans, New Orleans, Louisiana, United States
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States
- University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
- Children's Mercy Hospital, Kansas City, Missouri, United States
- Cardinal Glennon Children's Hospital, St Louis, Missouri, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- +10 more locations on ClinicalTrials.gov
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00055653 on ClinicalTrials.govOther trials for Tumor of hematopoietic and lymphoid tissues
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07249346Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell TransplantationHannah Choe, MD
- RECRUITINGPHASE1NCT06904066Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07270770BY002 IIT Study in R/R Acute LeukemiaThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1NCT07257419CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and LymphomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07249905Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaModeX Therapeutics, An OPKO Health Company
- RECRUITINGPHASE1, PHASE2NCT07471789Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).Gyala Therapeutics
- RECRUITINGNANCT07051525Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and FeverPeter MacCallum Cancer Centre, Australia
- RECRUITINGPHASE1NCT06441331Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsITM Solucin GmbH
See all trials for Tumor of hematopoietic and lymphoid tissues →